Detalle Publicación

ART%EF%BF%BD%EF%BF%BDCULO

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)

Autores: Sehouli, J.; Chekerov, R.; Reinthaller, A.; Richter, R.; González Martín, Antonio; Harter, P.; Woopen, H.; Petru, E.; Hanker, L. C.; Keil, E.; Wimberger, P.; Klare, P.; Kurzeder, C.; Hilpert, F.; Belau, A. K.; Zeimet, A.; Bover-Barcelo, I.; Canzler, U.; Mahner, S.; Meier, W.
Título de la revista: ANNALS OF ONCOLOGY
ISSN: 1569-8041
Volumen: 27
Número: 12
Páginas: 2236-2241
Fecha de publicación: 2016
Resumen:
The combination of carboplatin and topotecan was well tolerated with significant lower rates of severe hematological toxicities but did not improve PFS or OS in platinum-sensitive relapsed ovarian cancer compared with established standard regimens.
Impacto:
Google Scholar